Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2023 19:00 ET | Source: Bionomics Ltd

Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)

Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challengeResults achieved statistical significance in post-hoc analysis of...
February 23, 2023 06:00 ET | Source: Bionomics Ltd

Bionomics’ Half-Year Report

ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ: BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented...
January 30, 2023 18:23 ET | Source: Bionomics Ltd

Quarterly Activities and Cashflow Report

ADELAIDE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO,), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel,...
December 18, 2022 19:34 ET | Source: Bionomics Ltd

Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder

BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary EndpointSubjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to...
December 15, 2022 18:35 ET | Source: Bionomics Ltd

Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer

ADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric...
December 02, 2022 06:00 ET | Source: Bionomics Ltd

Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
November 21, 2022 18:13 ET | Source: Bionomics Ltd

Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States

ADELAIDE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel,...
November 16, 2022 18:36 ET | Source: Bionomics Ltd

Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States

ADELAIDE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel,...
November 02, 2022 06:00 ET | Source: Bionomics Ltd

Bionomics Limited to Participate in Upcoming November Investor Conferences

ADELAIDE, Australia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
October 25, 2022 06:00 ET | Source: Bionomics Ltd

Quarterly Activities Report for September 2022

ADELAIDE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric...